Evidence map›Paper›PMID 31853536›Full record

ArticleNucleic acids research2020

Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity.

Lena Voith von Voithenberg, Anna Fomitcheva Khartchenko, Deborah Huber, Peter Schraml, Govind V Kaigala

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Recent Advances in High-sensitivityActa histochemica et cytochemica · 2023
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lena Voith von VoithenbergIBM Research Zürich, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland.
Anna Fomitcheva KhartchenkoIBM Research Zürich, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland.
Deborah HuberIBM Research Zürich, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland.
Peter SchramlUniversity Hospital Zurich, Department of Pathology and Molecular Pathology, Schmelzbergstr. 12, CH-8091 Zurich, Switzerland.
Govind V KaigalaIBM Research Zürich, Säumerstrasse 4, CH-8803 Rüschlikon, Switzerland.
IBM Research - Zurich · CHUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiplexed RNA in situ hybridization for the analysis of gene expression patterns plays an important role in investigating development and disease. Here, we present a method for multiplexed RNA-ISH to detect spatial tumor heterogeneity in tissue sections. We made use of a microfluidic chip to deliver ISH-probes locally to regions of a few hundred micrometers over time periods of tens of minutes. This spatial multiplexing method can be combined with ISH-approaches based on signal amplification, with bright field detection and with the commonly used format of formalin-fixed paraffin-embedded tissue sections. By using this method, we analyzed the expression of HER2 with internal positive and negative controls (ActB, dapB) as well as predictive biomarker panels (ER, PgR, HER2) in a spatially multiplexed manner on single mammary carcinoma sections. We further demonstrated the applicability of the technique for subtype differentiation in breast cancer. Local analysis of HER2 revealed medium to high spatial heterogeneity of gene expression (Cohen effect size r = 0.4) in equivocally tested tumor tissues. Thereby, we exemplify the importance of using such a complementary approach for the analysis of spatial heterogeneity, in particular for equivocally tested tumor samples. As the method is compatible with a range of ISH approaches and tissue samples, it has the potential to find broad applicability in the context of molecular analysis of human diseases.

Indexed as

Biomarkers, TumorBreast NeoplasmsCell LineErb-b2 Receptor Tyrosine KinasesFemaleHumansIn Situ HybridizationLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesRNA, NeoplasmBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNA, Neoplasm

Identifiers

PMID31853536
PMCPMC7026647
OpenAlexW2995343920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.